孟鲁司特钠联合卡介菌多糖核酸治疗小儿变异性哮喘的效果观察(1)
[摘要] 目的 探讨孟鲁司特钠联合卡介菌多糖核酸治疗小儿咳嗽变异性哮喘的疗效及安全性。 方法 选取我院2010年5月～2013年5月收治入院的小儿咳嗽变异性哮喘患者200例作为研究对象，将其随机均分为实验组和对照组，每组100例。实验组给予孟鲁司特钠联合卡介菌多糖核酸治疗；对照组给予孟鲁司特钠治疗。比较两组患者的临床疗效及安全性。 结果 实验组治疗后总有效率明显高于对照组，两组比较差异有统计学意义(χ2=8.199，P<0.01)；与治疗前比较，两组治疗后血清IgE、IL-4、TNF-α水平均显著降低，差异有统计学意义(P<0.05)。实验组血清IgE、IL-4、TNF-α下降水平显著低于对照组，差异有统计学意义(P均<0.05)；实验组治疗后症状缓解时间和症状消失时间均显著短于对照组，两组比较差异有统计学意义(P均<0.05)；观察组复发率(4.0%)显著低于对照组(11.0%)，两组比较差异有统计学意义(χ2=4.585，P<0.05)。 结论 孟鲁司特钠联合卡介菌多糖核酸治疗小儿咳嗽变异性哮喘疗效显著，不良反应少，复发率低，安全性高，值得临床推广应用。
[关键词] 儿童咳嗽变异性哮喘；孟鲁司特钠；卡介菌多糖核酸；安全性
[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721(2016)02(b)-0023-03
Effect observation of montelukast sodium combined with BCG-polysaccharide nuceic acid in treating children with cough variant asthma
CHU Ming-hui
Department of Pediatrics，Central Hospital of Huludao City in Liaoning Province，Huludao 125001，China
[Abstract] Objective To explore the effect and safety of montelukast sodium combined with BCG-polysaccharide nuceic acid in treating children with cough variant asthma. Methods 200 children with cough variant asthma patients from May 2010 to May 2013 of our hospital were selected as study objects.Patients were randomly divided into experimental group and control group，and each group was 100 cases.Patients in experimental group were given montelukast sodium combined with BCG-polysaccharide nuceic acid and patients in control group were given montelukast sodium.Clinical effect and safety between two groups were compared. Results The total effective in experimental group was obvious higher than that of control group，and the difference was statistical significance(χ2=8.199，P<0.01).Compared with before treatment，the level of serum IgE，IL-4 and TNF-α decreased obvious after treatment，and the difference was statistical significance(P<0.05).The level of serum IgE，IL-4 and TNF-α in experimental group decreased more obvious than that of control group，and the difference was statistical significance (all P<0.05).After treatment，symptoms alleviated time and symptoms disappeared time in experimental group was obvious shorter than that of control group respectively，and the difference was statistical significance(all P<0.05).The recurrence rate was 4.0% in experimental group，obvious lower than that was 11.0% in control group，and the difference was statistical significance (χ2=4.585，P<0.05). Conclusion Montelukast sodium combined with BCG-polysaccharide nuceic acid in treating children with cough variant asthma has obvious effect，little adverse reaction，low recurrence rate and high safety.It is worth to popularize in clinic., http://www.100md.com(褚明慧)
[关键词] 儿童咳嗽变异性哮喘；孟鲁司特钠；卡介菌多糖核酸；安全性
[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721(2016)02(b)-0023-03
Effect observation of montelukast sodium combined with BCG-polysaccharide nuceic acid in treating children with cough variant asthma
CHU Ming-hui
Department of Pediatrics，Central Hospital of Huludao City in Liaoning Province，Huludao 125001，China
[Abstract] Objective To explore the effect and safety of montelukast sodium combined with BCG-polysaccharide nuceic acid in treating children with cough variant asthma. Methods 200 children with cough variant asthma patients from May 2010 to May 2013 of our hospital were selected as study objects.Patients were randomly divided into experimental group and control group，and each group was 100 cases.Patients in experimental group were given montelukast sodium combined with BCG-polysaccharide nuceic acid and patients in control group were given montelukast sodium.Clinical effect and safety between two groups were compared. Results The total effective in experimental group was obvious higher than that of control group，and the difference was statistical significance(χ2=8.199，P<0.01).Compared with before treatment，the level of serum IgE，IL-4 and TNF-α decreased obvious after treatment，and the difference was statistical significance(P<0.05).The level of serum IgE，IL-4 and TNF-α in experimental group decreased more obvious than that of control group，and the difference was statistical significance (all P<0.05).After treatment，symptoms alleviated time and symptoms disappeared time in experimental group was obvious shorter than that of control group respectively，and the difference was statistical significance(all P<0.05).The recurrence rate was 4.0% in experimental group，obvious lower than that was 11.0% in control group，and the difference was statistical significance (χ2=4.585，P<0.05). Conclusion Montelukast sodium combined with BCG-polysaccharide nuceic acid in treating children with cough variant asthma has obvious effect，little adverse reaction，low recurrence rate and high safety.It is worth to popularize in clinic., http://www.100md.com(褚明慧)